PARTNERSHIP OPPORTUNITIES
Free Shipping in the U.S. for orders over $1000. Shop Now>>
Formalin-fixed, paraffin-embedded human Spleen stained with VEGI Mouse Recombinant Monoclonal Antibody (rVEGI /1283).
Formalin-fixed, paraffin-embedded human Parathyroid Mass stained with VEGI Mouse Recombinant Monoclonal Antibody (rVEGI /1283).
SDS-PAGE Analysis of Purified VEGI Mouse Recombinant Monoclonal Antibody (rVEGI /1283). Confirmation of Purity and Integrity of Antibody.
Analysis of Protein Array containing more than 19,000 full-length human proteins using TNFS15 / VEGI Recombinant Mouse Monoclonal Antibody (rVEGI/1283). Z- and S- Score: The Z-score represents the strength of a signal that a monoclonal antibody (MAb) (in combination with a fluorescently-tagged anti-IgG secondary antibody) produces when binding to a particular protein on the HuProtTM array. Z-scores are described in units of standard deviations (SD's) above the mean value of all signals generated on that array. If targets on HuProtTM are arranged in descending order of the Z-score, the S-score is the difference (also in units of SD's) between the Z-score. S-score therefore represents the relative target specificity of a MAb to its intended target. A MAb is considered to specific to its intended target, if the MAb has an S-score of at least 2.5. For example, if a MAb binds to protein X with a Z-score of 43 and to protein Y with a Z-score of 14, then the S-score for the binding of that MAb to protein X is equal to 29.
VEGI is an anti-angiogenic cytokine that belongs to tumor necrosis factor superfamily, member 15 (TNFSF15). This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. Reduced expression of VEGI has been reported as a marker of poor prognosis in breast cancer.
There are no reviews yet.